Chamberlain University
LANIF • 355 NM
★ ★
C College of Nursing & Public Health
J O U R N E Y T O E X T R A O R D I N A R Y CO M PA S S I O N AT E C A R E
EST. 1889
MN 553 — Final Examination
A D VA N C E D P H A R M A CO LO G Y: P R E S C R I B I N G , P H A R M A CO K I N E T I CS & T H E R A P E U T I CS
INSTITUTION Chamberlain University COURSE CODE MN 553
PROGRAM Master of Science in Nursing (MSN / FNP) ACADEMIC YEAR
EXAM TITLE Final Examination – Advanced TOTAL QUESTIONS 45 Questions
Pharmacology
COURSE TITLE Advanced Pharmacology FORMAT Multiple Choice — Select the Single Best
Answer
EXAMINATION INSTRUCTIONS
▸ Select the single best answer for each multiple-choice question.
▸ This comprehensive final examination covers prescriptive authority, pharmacokinetics, pharmacodynamics, drug interactions,
antimicrobial therapy, cardiovascular medications, endocrine pharmacology, pain management, geriatric/pediatric
considerations, and pharmacoeconomics.
▸ Correct answers and detailed rationales appear below each question.
▸ All content is aligned with Chamberlain University MN 553 course competencies.
ADVANCED PHARMACOLOGY — COMPREHENSIVE FINAL Questions 1 – 45
1. Prescriptive authority for advanced practice nurses is regulated by:
A. The U.S. Food and Drug Administration (FDA)
B. The State Board of Nursing for each state
C. The American Medical Association
D. The Drug Enforcement Administration (DEA)
CORRECT ANSWER B — The State Board of Nursing for each state
RATIONALE Prescriptive authority is regulated at the state level by each State Board of Nursing, which determines scope
of practice, formulary restrictions, and requirements for controlled substance prescribing. The FDA (A)
approves drugs. The DEA (D) regulates controlled substances but does not grant prescriptive authority.
, 2. Drugs undergoing extensive first-pass effect are:
A. Rapidly metabolized by the liver and may have little if any desired action
B. Absorbed directly into systemic circulation without liver metabolism
C. Excreted unchanged by the kidneys
D. Only administered intravenously
CORRECT ANSWER A — Rapidly metabolized by the liver and may have little if any desired action
RATIONALE First-pass effect (presystemic metabolism) occurs when orally administered drugs are extensively
metabolized in the liver before reaching systemic circulation, significantly reducing bioavailability. This
explains why some drugs require higher oral doses or alternative routes (sublingual, parenteral).
3. A loading dose is administered to:
A. Gradually achieve drug levels in the therapeutic range
B. Rapidly achieve drug levels in the therapeutic range
C. Maintain steady-state concentrations during chronic therapy
D. Reduce the risk of adverse drug reactions
CORRECT ANSWER B — Rapidly achieve drug levels in the therapeutic range
RATIONALE A loading dose is a larger initial dose that quickly achieves therapeutic drug concentrations, particularly
important for drugs with long half-lives where waiting for steady state would delay therapeutic effect.
Maintenance doses (C) sustain levels after loading.
4. Investigational new drugs must be filed with which agency prior to human testing?
A. Drug Enforcement Administration (DEA)
B. State Board of Pharmacy
C. U.S. Food and Drug Administration (FDA)
D. National Institutes of Health (NIH)
CORRECT ANSWER C — U.S. Food and Drug Administration (FDA)
RATIONALE An Investigational New Drug (IND) application must be filed with the FDA before human clinical trials begin.
This application includes preclinical data, manufacturing information, and clinical protocols to ensure
participant safety.
5. The most common reason for medication nonadherence is:
A. Cost of medication
B. Asymptomatic conditions (patients don't feel the need to take medication)
C. Complex dosing regimens
D. Lack of access to pharmacy
CORRECT ANSWER B — Asymptomatic conditions (patients don't feel the need to take medication)
RATIONALE Nonadherence is most common with asymptomatic chronic conditions (hypertension, hyperlipidemia)
because patients lack immediate feedback linking medication to symptom relief. Reducing adverse effects
that patients find "irritating" (nausea, dizziness) improves adherence.
LANIF • 355 NM
★ ★
C College of Nursing & Public Health
J O U R N E Y T O E X T R A O R D I N A R Y CO M PA S S I O N AT E C A R E
EST. 1889
MN 553 — Final Examination
A D VA N C E D P H A R M A CO LO G Y: P R E S C R I B I N G , P H A R M A CO K I N E T I CS & T H E R A P E U T I CS
INSTITUTION Chamberlain University COURSE CODE MN 553
PROGRAM Master of Science in Nursing (MSN / FNP) ACADEMIC YEAR
EXAM TITLE Final Examination – Advanced TOTAL QUESTIONS 45 Questions
Pharmacology
COURSE TITLE Advanced Pharmacology FORMAT Multiple Choice — Select the Single Best
Answer
EXAMINATION INSTRUCTIONS
▸ Select the single best answer for each multiple-choice question.
▸ This comprehensive final examination covers prescriptive authority, pharmacokinetics, pharmacodynamics, drug interactions,
antimicrobial therapy, cardiovascular medications, endocrine pharmacology, pain management, geriatric/pediatric
considerations, and pharmacoeconomics.
▸ Correct answers and detailed rationales appear below each question.
▸ All content is aligned with Chamberlain University MN 553 course competencies.
ADVANCED PHARMACOLOGY — COMPREHENSIVE FINAL Questions 1 – 45
1. Prescriptive authority for advanced practice nurses is regulated by:
A. The U.S. Food and Drug Administration (FDA)
B. The State Board of Nursing for each state
C. The American Medical Association
D. The Drug Enforcement Administration (DEA)
CORRECT ANSWER B — The State Board of Nursing for each state
RATIONALE Prescriptive authority is regulated at the state level by each State Board of Nursing, which determines scope
of practice, formulary restrictions, and requirements for controlled substance prescribing. The FDA (A)
approves drugs. The DEA (D) regulates controlled substances but does not grant prescriptive authority.
, 2. Drugs undergoing extensive first-pass effect are:
A. Rapidly metabolized by the liver and may have little if any desired action
B. Absorbed directly into systemic circulation without liver metabolism
C. Excreted unchanged by the kidneys
D. Only administered intravenously
CORRECT ANSWER A — Rapidly metabolized by the liver and may have little if any desired action
RATIONALE First-pass effect (presystemic metabolism) occurs when orally administered drugs are extensively
metabolized in the liver before reaching systemic circulation, significantly reducing bioavailability. This
explains why some drugs require higher oral doses or alternative routes (sublingual, parenteral).
3. A loading dose is administered to:
A. Gradually achieve drug levels in the therapeutic range
B. Rapidly achieve drug levels in the therapeutic range
C. Maintain steady-state concentrations during chronic therapy
D. Reduce the risk of adverse drug reactions
CORRECT ANSWER B — Rapidly achieve drug levels in the therapeutic range
RATIONALE A loading dose is a larger initial dose that quickly achieves therapeutic drug concentrations, particularly
important for drugs with long half-lives where waiting for steady state would delay therapeutic effect.
Maintenance doses (C) sustain levels after loading.
4. Investigational new drugs must be filed with which agency prior to human testing?
A. Drug Enforcement Administration (DEA)
B. State Board of Pharmacy
C. U.S. Food and Drug Administration (FDA)
D. National Institutes of Health (NIH)
CORRECT ANSWER C — U.S. Food and Drug Administration (FDA)
RATIONALE An Investigational New Drug (IND) application must be filed with the FDA before human clinical trials begin.
This application includes preclinical data, manufacturing information, and clinical protocols to ensure
participant safety.
5. The most common reason for medication nonadherence is:
A. Cost of medication
B. Asymptomatic conditions (patients don't feel the need to take medication)
C. Complex dosing regimens
D. Lack of access to pharmacy
CORRECT ANSWER B — Asymptomatic conditions (patients don't feel the need to take medication)
RATIONALE Nonadherence is most common with asymptomatic chronic conditions (hypertension, hyperlipidemia)
because patients lack immediate feedback linking medication to symptom relief. Reducing adverse effects
that patients find "irritating" (nausea, dizziness) improves adherence.
